ENANTA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.1 USD | -10.27% |
|
-4.66% | +39.21% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 70.34M | Sales 2025 * | 72.77M | Capitalization | 309M |
|---|---|---|---|---|---|
| Net income 2024 * | -125M | Net income 2025 * | -113M | EV / Sales 2024 * | 4.39 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.24 x |
| P/E ratio 2024 * |
-2.52
x | P/E ratio 2025 * |
-3.08
x | Employees | 145 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Enanta Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | -10.27% | ||
| 1 week | -4.66% | ||
| Current month | -4.66% | ||
| 1 month | -19.93% | ||
| 3 months | +6.85% | ||
| 6 months | +43.80% | ||
| Current year | +39.21% |
1 week
11.60
15.38
1 month
11.6017.03
Current year
9.2417.80
1 year
8.0836.04
3 years
8.08102.00
5 years
8.08102.00
10 years
8.08127.77
| Managers | Title | Age | Since |
|---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 03-08-31 |
| Chief Tech/Sci/R&D Officer | 50 | 22-08-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 20-06-28 |
Lesley Russell
BRD | Director/Board Member | 63 | 16-11-17 |
Bruce Carter
CHM | Chairman | 80 | 13-11-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 13.1 | -10.27% | 264 668 |
| 24-05-06 | 14.6 | -3.76% | 116,822 |
| 24-05-03 | 15.17 | +9.06% | 124,535 |
| 24-05-02 | 13.91 | +2.58% | 116,755 |
| 24-05-01 | 13.56 | -1.31% | 139,736 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotes
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).
Calendar
2024-08-05
- Q3 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
14.6
USD
Average target price
20.5
USD
Spread / Average Target
+40.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.21% | 309M | |
| +21.74% | 46.81B | |
| -0.97% | 41.37B | |
| +47.07% | 41.29B | |
| -3.52% | 28.87B | |
| +11.12% | 26.06B | |
| -19.37% | 19.13B | |
| +31.18% | 12.39B | |
| -0.04% | 12.08B | |
| +0.39% | 11.96B |
- Stock Market
- Equities
- ENTA Stock